The stock of BridgeBio Pharma Inc (BBIO) has seen a 5.87% increase in the past week, with a 17.27% gain in the past month, and a 47.67% flourish in the past quarter. The volatility ratio for the week is 2.72%, and the volatility levels for the past 30 days are at 3.51% for BBIO. The simple moving average for the last 20 days is 6.91% for BBIO stock, with a simple moving average of 41.60% for the last 200 days.
Is It Worth Investing in BridgeBio Pharma Inc (NASDAQ: BBIO) Right Now?
The 36-month beta value for BBIO is also noteworthy at 1.23. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 6 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for BBIO is 160.86M, and at present, short sellers hold a 13.13% of that float. The average trading volume of BBIO on July 09, 2025 was 3.09M shares.
BBIO) stock’s latest price update
The stock price of BridgeBio Pharma Inc (NASDAQ: BBIO) has surged by 4.86% when compared to previous closing price of $43.19, but the company has seen a 5.87% gain in its stock price over the last five trading sessions. youtube.com reported 2025-07-07 that Jared Holz, Mizuho, joins ‘Closing Bell Overtime’ to discuss if the biotech sector is ready for a breakout.
Analysts’ Opinion of BBIO
Wolfe Research, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $49. The rating they have provided for BBIO stocks is “Outperform” according to the report published on June 17th, 2025.
Redburn Atlantic gave a rating of “Buy” to BBIO, setting the target price at $50 in the report published on March 31st of the current year.
BBIO Trading at 18.46% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.42% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Kumar Neil, who sale 40,000 shares at the price of $42.73 back on Jul 02 ’25. After this action, Kumar Neil now owns 955,686 shares of BridgeBio Pharma Inc, valued at $1,709,050 using the latest closing price.
Kumar Neil, the Chief Executive Officer of BridgeBio Pharma Inc, sale 40,000 shares at $42.54 during a trade that took place back on Jul 01 ’25, which means that Kumar Neil is holding 975,686 shares at $1,701,400 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -5.48 for the present operating margin
- 0.97 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -5.24. The total capital return value is set at -0.96.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -49.43. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -5.91.
Currently, EBITDA for the company is -436.83 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 63.21. The receivables turnover for the company is 1.11for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.57.
Conclusion
In summary, BridgeBio Pharma Inc (BBIO) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
